3-Desacetyl Vecuronium Bromide is the primary active metabolite of Vecuronium Bromide, a non-depolarizing neuromuscular blocking agent used in anesthesia. It is formed via deacetylation in the liver and exhibits approximately 50-80% of the neuromuscular blocking potency of the parent compound. This metabolite contributes to the overall duration of action of Vecuronium by competitively antagonizing acetylcholine at nicotinic receptors in the neuromuscular junction, leading to reversible skeletal muscle relaxation. It is commonly used as a reference standard in pharmaceutical analysis, pharmacokinetic studies, and research on neuromuscular blockers. Due to its role in metabolism, it has minimal cardiovascular effects similar to Vecuronium. Elimination occurs primarily via biliary excretion.